Truist Securities analyst Jennifer Demba downgrades Southern States (NASDAQ:SSBK) from Buy to Hold.
European Commission Approves Pfizer’s TALZENNA In Combination With XTANDI For Adult Patients With Metastatic Castration-Resistant Prostate Cancer
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the Europe UnionPfizer Inc. (NYSE:PFE) today announced that the European Commission (EC) has
